Organic Process Research & Development 2004, 8, 360−362
An Improved Process for the Preparation of Trimethylhydrazine and Its
Coupling with an Activated Acid Intermediate
Silvina Garc´ıa-Rubio,* Chandra D. Wilson, Deborah A. Renner, John O. Rosser, Debasis Patra, J. Gregory Reid, and
Seemon H. Pines
Albany Molecular Research, Inc., Syracuse Research Center, 7001 Performance DriVe,
North Syracuse, New York 13212, U.S.A.
Abstract:
Reaction of 1,1-dimethylhydrazine with ethyl formate was
executed easily on a 5-kg scale according to a procedure
already described4c and yielded 1-formyl-2,2-dimethyl-
hydrazine (4) in 89% yield (Scheme 2).
The reduction of 4 with LiAlH4 was initially done in THF
at room temperature. After an exothermic quench (external
cooling at -35 °C was required to control the heat release)
using ethylene glycol,5 a thick, gummy mixture resulted that
stuck to the stir shaft and further caused its destruction.
Eventually, TMH (5) was obtained as a 5% w/w solution
by co-distillation with THF,6 requiring additional THF to
be periodically added to distill all of the TMH out.
Trimethylhydrazine (TMH) was prepared in two steps from
1,1-dimethylhydrazine, using an easy to scale-up procedure that
avoided difficult acid-base extractions. The procedure provided
TMH as a solution in 1,4-dioxane, in a form that was easy and
safe to handle in a coupling with an enantiomerically pure,
sterically hindered, Boc-protected-amino acid, 1. This key
coupling reaction in the preparation of 3 was accomplished
through the corresponding acid chloride, thereby avoiding the
use of expensive coupling reagents.
In an attempt to obtain a more concentrated solution of
5, 1,4-dioxane was chosen as the reaction solvent. After the
ethylene glycol quench, a gummy mixture resulted again,
and TMH and 1,4-dioxane were co-distilled, resulting in four
fractions, the first two of which contained TMH in higher
concentration (13% w/w). The last fractions collected did
Introduction
Trimethylhydrazine (TMH) is a ubiquitous component in
the preparation of new chemical entities.1 En route to
obtaining multigram quantities of a new drug candidate
possessing growth hormone releasing properties (3), the
necessity for a safe and reliable process for the preparation
of TMH on large scale became evident. Additionally,
coupling TMH with sterically hindered acid 1 using an
inexpensive coupling agent or, better yet, through a reactive
intermediate of 1, such as its acid chloride, was desired
(Scheme 1).
1
not contain product, as monitored by H NMR analysis.
Exothermicity of the ethylene glycol quench of excess
LiAlH4 required the use of a reactor at -35 °C (external
temperature) while the mixture of TMH (plus cosolvent) had
to be distilled at about 100 °C (internal temperature).
Equipment restrictions meant that these operations had to
be done in different reactors. Due to the thick slurry nature
of the resulting mixture and stirring difficulties encountered
during the quench, a transfer to a second container for
distillation was impossible without the potential exposure
of operating personnel to TMH.7 These mechanical issues
were circumvented by quenching the reaction with 1,2-
propylene glycol, which resulted in a slurry that was easy
to stir, both at room temperature and at 100 °C and which
was transferred using vacuum to the distillation reactor. Thus,
exposure of operating personnel to TMH was eliminated.
Scale-up of the reaction to 2 kg was uneventful, and the
mixture of product and 1,4-dioxane was distilled (92-96 °C).
In this way, a less concentrated solution of TMH (7.4% w/w)
was obtained, even when the overall yield remained un-
changed (70%).8 Performance of the TMH solution in 1,4-
Results and Discussion
Methods reported in the literature for the preparation of
TMH include the reduction of methylene dimethylhydrazine
using LiAlH4 or catalytic hydrogenation2,3 as well as the
reduction of N-formyl dimethylhydrazine with LiAlH4.4
Usually, TMH was isolated as the HCl salt using acid-base
extractions.
* To whom correspondence should be addressed. E-mail: silvina.garcia@
albmolecular.com.
(1) (a) Andersen, P.; Ankersen, M.; Jessen, C. U.; Lehman, S. V. Org. Proc.
Res. DeV. 2002, 6, 367. (b) Hanefeld, W.; Von Goesseln, H. J. Arch. Pharm.
(Weinheim, Ger.) 1991, 324, 917. (c) Riebli, P. EP 430033 A2 19910605,
1991. (d) Chong, J. M.; Mar, E. Tetrahedron Lett. 1990, 13, 1981. (e) Walter,
W.; Krische, B.; Voss, J. J. Chem. Res., Synop.1978, 332. (f) Lowrie, H. S.
U.S. Patent 19650506, 1967. (g) Levitt, G. U.S. Patent 19670509, 1967.
(h) Lowrie, H. S. J. Med. Chem. 1966, 9, 664. (i) Sensi, P.; Maggi, N.;
Ballota, R.; Fu¨re`sz, S.; Pallanza, R.; Arioli, V. J. Med. Chem. 1964, 7, 596.
(2) (a) Class, J. B.; Aston, J. G. J. Am. Chem. Soc. 1951, 73, 2359. (b) Class,
J. B.; Aston, J. G.; Oakwood, T. S. J. Am. Chem. Soc. 1953, 75, 2937.
(3) (a) Horvitz, D. U.S. Patent 3,182,087, 1965. (b) Sidi, H.; Paramus, N. J.
U.S. Patent 3,517,064, 1970.
(4) (a) Klages, F.; Nober, G.; Kircher, K.; Bock, M. Justus Liebigs Ann. Chem.
1941, 547, 12, 32. (b) Hinman, R. L. J. Am. Chem. Soc. 1956, 78, 1645. (c)
Beltrami, R. T.; Bisell, E. R. J. Am. Chem. Soc. 1956, 78, 2467. (d)
Andersen, P.; Ankersen, M.; Jessen, C. U.; Lehman, S. V. Org. Process
Res. DeV. 2002, 6, 367.
(5) For a discussion of the complexation on aluminum ions with polydentate
ligands such as ethylene glycol, see: McMahon, C. N.; Alemany, L.;
Callender, R. L.; Bott, S. G.; Barron, A. R. Chem. Mater. 1999, 11, 3181.
Saraswathi, M.; Miller, J. M. Can. J. Chem. 1996, 74, 2221.
(6) The concentration of 5 in THF was determined by integration of the CH3
signal in the 1H NMR spectra.
(7) For information on the toxicity of TMH, see: Toth, B. Cancer 1977, 40,
2427. Nagel, D.; Toth, B.; Kupper, R.; Erickson, J. J. Natl. Cancer Inst.
1976, 57, 187.
360
•
Vol. 8, No. 3, 2004 / Organic Process Research & Development
10.1021/op0342022 CCC: $27.50 © 2004 American Chemical Society
Published on Web 03/26/2004